Patiromer Sorbitex Calcium Patent Expiration
Patiromer Sorbitex Calcium is Used for lowering high levels of potassium in the blood. It was first introduced by Vifor Pharma Inc
Patiromer Sorbitex Calcium Patents
Given below is the list of patents protecting Patiromer Sorbitex Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veltassa | US11123363 | Potassium-binding agents for treating hypertension and hyperkalemia | Oct 08, 2033 | Vifor Pharma |
| Veltassa | US9492476 | Potassium-binding agents for treating hypertension and hyperkalemia | Oct 08, 2033 | Vifor Pharma |
| Veltassa | US9925212 | Potassium-binding agents for treating hypertension and hyperkalemia | Oct 08, 2033 | Vifor Pharma |
| Veltassa | US8337824 | Linear polyol stabilized polyfluoroacrylate compositions | May 29, 2030 | Vifor Pharma |
| Veltassa | US8147873 | Methods and compositions for treatment of ion imbalances | Jun 20, 2028 | Vifor Pharma |
| Veltassa | US8282913 | Ion binding polymers and uses thereof | May 29, 2027 | Vifor Pharma |
| Veltassa | US8216560 | Ion binding polymers and uses thereof | Mar 14, 2027 | Vifor Pharma |
| Veltassa | US7556799 | Ion binding polymers and uses thereof | Feb 27, 2025 | Vifor Pharma |
| Veltassa | US10485821 | Ion binding polymers and uses thereof |
Mar 30, 2024
(Expired) | Vifor Pharma |
| Veltassa | US8287847 | Ion binding polymers and uses thereof |
Mar 30, 2024
(Expired) | Vifor Pharma |
| Veltassa | US8475780 | Ion binding polymers and uses thereof |
Mar 30, 2024
(Expired) | Vifor Pharma |
| Veltassa | US8778324 | Ion binding polymers and uses thereof |
Mar 30, 2024
(Expired) | Vifor Pharma |
| Veltassa | US8889115 | Ion binding polymers and uses thereof |
Mar 30, 2024
(Expired) | Vifor Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Patiromer Sorbitex Calcium's patents.
Latest Legal Activities on Patiromer Sorbitex Calcium's Patents
Given below is the list recent legal activities going on the following patents of Patiromer Sorbitex Calcium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Jun, 2024 | US8337824 |
| Maintenance Fee Reminder Mailed Critical | 03 Jun, 2024 | US8287847 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Apr, 2024 | US8282913 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jan, 2024 | US8216560 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8147873 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2023 | US10485821 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 May, 2022 | US8889115 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jan, 2022 | US8778324 |
| Post Issue Communication - Certificate of Correction | 25 Oct, 2021 | US11123363 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Sep, 2021 | US9925212 |
Patiromer Sorbitex Calcium's Family Patents
